title: Implications of protein- and Peptide-based nanoparticles as potential vehicles for anticancer drugs.
abstract: Protein-based nanocarriers have gained considerable attention as colloidal carrier systems for the delivery of anticancer drugs. Protein nanocarriers possess various advantages including their low cytotoxicity, abundant renewable sources, high drug-binding capacity, and significant uptake into the targeted tumor cells. Moreover, the unique protein structure offers the possibility of site-specific drug conjugation and tumor targeting using various ligands modifying the surface of protein nanocarriers. In this chapter, we highlight the most important applications of protein nanoparticles (NPs) for the delivery of anticancer drugs. We examine the various techniques that have been utilized for the preparation of anticancer drug-loaded protein NPs. Finally, the current chapter also reviews the major outcomes of the in vitro and in vivo investigations of surface-modified tumor-targeted protein NPs.
authors.affiliation: Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Electronic address: dr_ahmedelzoghby@yahoo.com.
authors.forename: Ahmed O
authors.initials: AO
authors.lastname: Elzoghby
authors.affiliation: Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
authors.forename: Mayada M
authors.initials: MM
authors.lastname: Elgohary
authors.affiliation: Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
authors.forename: Nayra M
authors.initials: NM
authors.lastname: Kamel
mesh_terms: D000418:Albumins / Q000737:chemistry; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D004549:Elastin / Q000737:chemistry; D005780:Gelatin / Q000737:chemistry; D005903:Gliadin / Q000737:chemistry; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008894:Milk Proteins / Q000737:chemistry; D058990:Molecular Targeted Therapy; D009113:Muramidase / Q000737:chemistry; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D055672:Static Electricity; D015028:Zein / Q000737:chemistry
chemical_list: D000418:Albumins; D000970:Antineoplastic Agents; D008894:Milk Proteins; D005780:Gelatin; D004549:Elastin; D005903:Gliadin; D015028:Zein; D009113:Muramidase
keywords: Anticancer drugs; Protein nanoparticles; Surface modification; Tumor-targeting